OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Jan 2016
At a glance
- Drugs Ovarian cancer vaccine (Primary)
- Indications Ovarian cancer
- Focus Pharmacodynamics
- Sponsors AVAX Technologies
- 26 Jan 2016 Results published in an Avax media release.
- 02 Dec 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 02 Dec 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.